Development asset linked to Sun Yat-sen University in public FDA and regional records.
pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
广州市新港西路135号, CN HQ
3,680 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
Sun Yat-sen University pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sun Yat-sen University drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Sun Yat-sen University in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
serplulimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sun Yat-sen University's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
surufatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Sun Yat-sen University's portfolio. Molecular target: Fibroblast growth factor receptor 1.
- Target
- Fibroblast growth factor receptor 1
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.
-
Development asset linked to Sun Yat-sen University in public FDA and regional records. Molecular target: Vasopressin V1 receptor.
- Target
- Vasopressin V1 receptor
- Mechanism
- Vasopressin V2 receptor binding agent
-
Development asset linked to Sun Yat-sen University in public FDA and regional records.